NH TherAguix is pioneering the use of nanomedicine to enhance the effectiveness of radiotherapy in cancer treatment through its innovative product, AGuIX®. This nanodrug is designed to improve the pharmacological properties of radiotherapy by enabling targeted bio-distribution within tumors, which allows it to act directly at the tumor site. AGuIX® has shown potential across various cancer types, offering hope for patients with unmet medical needs. The company emphasizes the importance of its ongoing clinical trials, which are critical for validating the efficacy and safety of AGuIX® in combination with traditional cancer treatments.

The clinical research surrounding AGuIX® has yielded promising results, particularly in trials focused on brain metastases. The drug has demonstrated a favorable safety profile and rapid renal elimination, which is crucial for minimizing side effects. Notably, studies have shown a correlation between the dosage of AGuIX® and tumor volume reduction, indicating its effectiveness as a radiosensitizer. The positive outcomes from these trials have been published in reputable scientific journals, underscoring the potential of AGuIX® to significantly improve treatment options for patients undergoing radiotherapy.

France

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Cancer

Central Nervous System (CNS)

NH TherAguix

Brain metastasis

NANORAD 2

Small Molecule Pharmaceuticals

NANOBRAINMETS

Glioblastoma

NANO-GBM﻿﻿

Non-small cell lung carcinoma

NANOSMART

Cervical cancer

NANOCOL

Europe - West

NanoMedicine/Nanotechnology

Radiopharmaceuticals/Radiotherapies

Therapeutic

NH TherAguix

Company Details